120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于 6-乙酰氧基阿诺蝶呤耐药相关程序性细胞死亡基因预测前列腺腺癌复发预后和免疫状态
Received 8 July 2025
Accepted for publication 2 December 2025
Published 31 January 2026 Volume 2026:18 552328
DOI https://doi.org/10.2147/CMAR.S552328
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Seema Singh
Jie Cheng,1 Dongdong Mao2
1Department of Anesthesiology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Urology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, People’s Republic of China
Correspondence: Dongdong Mao, Email 15053688671@163.com
Purpose: This study aims to reveal the potential mechanism and potential prognostic markers of programmed cell death (PCD) genes associated with 6-acetoxy-anopterine (6-AA) resistance in prostate adenocarcinoma (PRAD).
Patients and Methods: The differentially expressed programmed cell death genes (DEPGs) associated with 6-AA resistance were revealed based on the The Cancer Genome Atlas (TCGA)-PRAD database. Then, a prognostic risk prediction model was established. Moreover, the relationship between the risk model and the immune microenvironment of PRAD samples was revealed, followed by the characteristics and mechanisms investigation of immune cell infiltration in different risk groups. Furthermore, the application prospects of the risk model in predicting drug response sensitivity were explored. Finally, the verification analysis was performed on signature genes using qPCR analysis.
Results: A total of totally 57 DEPGs were screened, and these genes mainly assembled in cysteine-type endopeptidase activity functions. The nomogram and survival analysis proved the prognostic value of signatures. Immune infiltration analysis revealed the dyregulation of memory CD4+ T cells between different risk groups. Moreover, 3 clusters were revealed in current study. Finally, the mRNA expression levels of six signatures (TOP2A, PABPN1, BCL2L12, TRIM14, PIK3R1 and LAPTM4B) in the verification analysis were consistent with the findings of our current bioinformatic study.
Conclusion: TOP2A, PABPN1, BCL2L12, TRIM14, PIK3R1 and LAPTM4B were novel PCD-related prognostic markers for PRAD. BCL2L12 might take part in the resistance of 6-AA in PRAD via the cysteine-type endopeptidase activity pathway.
Keywords: prostate adenocarcinoma, programmed cell death, 6-acetoxy-anopterine resistance, prognostic gene, qPCR
1Department of Anesthesiology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Urology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, People’s Republic of China
Correspondence: Dongdong Mao, Email 15053688671@163.com
Purpose: This study aims to reveal the potential mechanism and potential prognostic markers of programmed cell death (PCD) genes associated with 6-acetoxy-anopterine (6-AA) resistance in prostate adenocarcinoma (PRAD).
Patients and Methods: The differentially expressed programmed cell death genes (DEPGs) associated with 6-AA resistance were revealed based on the The Cancer Genome Atlas (TCGA)-PRAD database. Then, a prognostic risk prediction model was established. Moreover, the relationship between the risk model and the immune microenvironment of PRAD samples was revealed, followed by the characteristics and mechanisms investigation of immune cell infiltration in different risk groups. Furthermore, the application prospects of the risk model in predicting drug response sensitivity were explored. Finally, the verification analysis was performed on signature genes using qPCR analysis.
Results: A total of totally 57 DEPGs were screened, and these genes mainly assembled in cysteine-type endopeptidase activity functions. The nomogram and survival analysis proved the prognostic value of signatures. Immune infiltration analysis revealed the dyregulation of memory CD4+ T cells between different risk groups. Moreover, 3 clusters were revealed in current study. Finally, the mRNA expression levels of six signatures (TOP2A, PABPN1, BCL2L12, TRIM14, PIK3R1 and LAPTM4B) in the verification analysis were consistent with the findings of our current bioinformatic study.
Conclusion: TOP2A, PABPN1, BCL2L12, TRIM14, PIK3R1 and LAPTM4B were novel PCD-related prognostic markers for PRAD. BCL2L12 might take part in the resistance of 6-AA in PRAD via the cysteine-type endopeptidase activity pathway.
Keywords: prostate adenocarcinoma, programmed cell death, 6-acetoxy-anopterine resistance, prognostic gene, qPCR